Study B: Ad libitum cannabis use for four weeks or no cannabis use / Obesity / Study A: Single use of cannabis flower product · Observational Study

Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

ClinicalTrials.gov · August 6, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registry record for a completed observational study examining acute and chronic effects of cannabis on inflammation and insulin sensitivity in individuals with type 2 diabetes and obesity. No results are posted in this registry record, so no efficacy or safety conclusions can be drawn.

What was studied

Observational. Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity; age from 21 Years; to 40 Years. Intervention: Study A; Study B. Compared with: Study A: Baseline (pre-use). Study B: Matched control group with no cannabis use.. n = 233. 1 site: United States.

Key findings

Safety

Results are not reported in this registry record; no efficacy or safety outcomes available.

Who this may help

No clinical impact can be assessed from this registry record as results are not posted. Clinicians and researchers should await publication of results before drawing conclusions about cannabis effects on inflammation or insulin sensitivity.

Plain-language summary

Registry record for an observational study with completed enrollment; no results posted, so evidence quality cannot be assessed.

Study design

As stated by the source record.

MethodsOther model. Prospective time perspective. Primary outcome measures: Markers of Inflammation (assessed at Study A: Difference between cytokines at baseline and cytokines one week later…); Change in Matsuda Index of Insulin Sensitivity (assessed at Study A: Baseline versus after acute use one week later of cannabis product. St…); Change in Plasma Glucose (assessed at Study A: Baseline versus one week later after acute use of cannabis product. St…); Change in Plasma Insulin (assessed at Study A: Baseline versus one week later after acute use of cannabis product. St…)

DesignObservational

PopulationType 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity; age from 21 Years; to 40 Years

Sample size233

InterventionStudy A; Study B

ComparatorStudy A: Baseline (pre-use). Study B: Matched control group with no cannabis use.

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Sample size233

Study typeObservational

Primary outcome: Markers of Inflammation (Study A)Difference between cytokines at baseline and one week later after acute cannabis use

Primary outcome: Markers of Inflammation (Study B)Change from baseline to four weeks

Primary outcome: Matsuda Index of Insulin Sensitivity (Study A)Baseline versus one week later after acute cannabis use

Primary outcome: Matsuda Index of Insulin Sensitivity (Study B)Two tests separated by four weeks

Primary outcome: Plasma Glucose (Study A)Baseline versus one week later

Primary outcome: Plasma Glucose (Study B)Baseline to four weeks

Clinical bottom line

Caveats

Results are not reported in this registry record; no efficacy or safety outcomes available.
Allocation of 233 participants between Study A and Study B arms is not specified.
No information on matching criteria for control group or adjustment for confounders.
Observational design limits causal inference; unmeasured confounding and selection bias cannot be excluded.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Observational design with two parallel arms; no randomization or blinding stated.

Directness

moderate

Direct measurement of inflammation markers and insulin sensitivity in target conditions.

Consistency

insufficient

Registry record only; no results reported for consistency assessment.

Risk of bias

limited

Observational design without randomization or blinding introduces selection and confounding bias.

Sample adequacy

moderate

233 participants enrolled across two study arms; allocation between arms not specified.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT04114903). This is a study registration, not published results. Lead sponsor: University of Colorado, Boulder. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 233 participants (ACTUAL). Conditions: Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity. Interventions: OTHER: Study A: Single use of cannabis flower product; OTHER: Study B: Ad libitum cannabis use for four weeks or no cannabis use. Primary outcome measures: Markers of Inflammation , Study A: Difference between cytokines at baseline and cytokines one week later after acute use of cannabis product. Study B: Change from baseline to four weeks; Change in Matsuda Index of Insulin Sensitivity , Study A: Baseline versus after acute use one week later of cannabis product. Study B: The two tests will be separated by four weeks; Change in Plasma Glucose , Study A: Baseline versus one week later after acute use of cannabis product. Study B: The two tests will be separated by four weeks; Change in Plasma Insulin , Study A: Baseline versus one week later after acute use of cannabis product. Study B: Baseline versus four weeks later. Brief summary: This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study employs two observational designs: 1) A study of acute effects with intermittent cannabis users and 2) A study in which current cannabis users will select one of three cannabis strains for four weeks and are compared to a matched control group who do not use cannabis to study chronic effects. Blood levels of THC and CBD, inflammatory biomarkers, and insulin resistance will be measured in both studies.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Study B: Ad libitum cannabis use for four weeks or no cannabis useUniversity of Colorado, BoulderObesityStudy A: Single use of cannabis flower productCannabis UseNCT04114903Type 2 Diabetes